Is It Safe to Take SSRI Antidepressants During Pregnancy? Relapse Risks vs Fetal Safety Evidence
Discontinuing SSRIs during pregnancy more than doubles maternal depression relapse rates (RR 2.30) without strong evidence of direct teratogenicity once psychiatric confounders are controlled. Here is an evidence-based clinical guide to shared decision-making.
The Shift in Perinatal Antidepressant Guidance
For years, pregnant individuals taking selective serotonin reuptake inhibitors (SSRIs) faced significant stigma and advice to abruptly discontinue medication upon discovering pregnancy. Modern maternal-fetal medicine research has fundamentally transformed this clinical perspective. Contemporary epidemiological studies demonstrating that when researchers control for confounding factors such as underlying maternal illness severity, lifestyle variables, and concurrent exposures, the absolute risk of major congenital malformations directly attributable to SSRI medications approaches the baseline population rate.
Understanding the Relapse Risk: Relative Risk 2.30
The most substantial clinical risk associated with stopping antidepressants in pregnancy is depressive and anxious relapse. Prospective studies indicate that patients who discontinue antidepressant maintenance therapy experience a relapse rate exceeding 60%, compared to roughly 26% among those who maintain their stable regimen (relative risk 2.30). Gestational depression carries serious physiological implications, including impaired prenatal care adherence, heightened cortisol exposure, increased risk of preterm delivery, and severe postpartum mood disorders.
Evaluating Neonatal Behavioral Adaptation Syndrome (NBAS)
A primary consideration discussed during prenatal consultations is Neonatal Behavioral Adaptation Syndrome (NBAS). Occurring in approximately 20% to 30% of infants exposed to SSRIs near delivery, NBAS manifests as mild, transient symptoms like mild jitteriness, sleep pattern variation, or mild respiratory adjustments. These symptoms typically resolve spontaneously within 48 to 72 hours under routine hospital observation and do not require separation from the parent or neonatal intensive care admission.
Certified Nurse-Midwives and Perinatal Prescribing Authority in Arizona
In Arizona, Certified Nurse-Midwives (CNMs) practice as independent Advanced Practice Registered Nurses with full prescriptive authority for Schedule II through V medications. CNMs are extensively trained to screen for perinatal mental health conditions, evaluate medication safety profiles, adjust dosages to account for expanded gestational plasma volume, and collaborate with reproductive psychiatrists and OB/GYN physicians for complex presentations.
The Structured Shared Decision-Making Framework
Clinical experts recommend using a structured shared decision-making conversation that weighs each patient's individual psychiatric history against potential infant considerations. Clinicians evaluate past episode severity, past response to non-pharmacological therapy (such as CBT), and postpartum support systems, ensuring that maternal stability remains the central priority throughout the perinatal continuum.
More educational guides
Educational content only. Not individual medical advice. Confirm hospital policies and Arizona Board of Nursing guidance with your care team. Sources